7,561.01

-19.06

-0.25%

52,068.69

+298.38

+0.58%

25,259.18

-177.82

-0.70%

2,813.92

+2.07

+0.07%

4.8960

-0.0330

-0.67%

21.04

+1.62

+8.37%

3,955.00

+56.10

+1.44%

76,725.21

-960.13

-1.24%

Crude Oil Dec 26

96.78

-7.34

-7.05%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

NeuroSense Therapeutics Ltd. (NRSN)

1.4000 -0.5900 (-29.65%)

As of 2:46:41 PM EST. Market Open.

Loading Chart for NRSN

Chart Range Bar

Interval:

In partnership with ChartIQ

NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data

NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

NeuroSense Issues CEO Letter to Shareholders

NeuroSense Issues CEO Letter to Shareholders

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Mobilize your Website

View Site in Mobile | Classic

Share by: